Memphis Zoo says attendance dropped after 2022 crimes, leading to deficits
MEMPHIS, Tenn. — The Memphis Zoo is asking city and county governments for $3 million in operational support, saying attendance has seen a 'tremendous drop' due to visitors' perception of safety in the city after some high-profile crimes.
Zoo officials shared attendance and revenue numbers with Memphis City Council members Tuesday, showing more than 1 million visitors to the zoo in 2019, and again in 2022 after attendance rebounded following the COVID pandemic closure.
But those numbers dipped by close to 20% beginning in 2023, leading to operating deficits the past two years.
'We saw a tremendous decrease in our attendance,' said Matt Thompson, president and CEO of the Memphis Zoo. 'If people aren't coming through our gate, then we aren't making revenue.'
State commits $20M for Memphis Zoo expansion
Thompson told council members the decline was directly related to the kidnapping and killing of Eliza Fletcher and the mass shooting carried out by Ezekiel Kelly.
Both crimes struck in the Midtown area in late 2022, and Thompson said they scared away visitors who have never come back.
'We were told directly by our members that people were nervous to come back into the city,' Thompson said. 'We've seen some people leave the city, we've seen that kind of thing. Our numbers have been very, very slow to come back.'
The revenue decline is creating a need for an additional $3 million, Thompson said, and the zoo is asking both the city and county for $1.5 million each. The zoo plans to use that money for deferred maintenance.
The city's management fee for the zoo is currently $1.2 million, the same as it was in 1989, Thompson said.
Still, there were many positive notes in the zoo's presentation. The Memphis Zoo is the top attraction in West Tennessee and was rated the No. 2 zoo in the country, with 52% of visitors coming from outside the region, creating an economic impact of $89.4 million.
SCSO says mom who drove into pond in Cordova was not drugged
The Memphis Zoo is undertaking a $250 million campus plan that will add an Africa exhibit featuring elephants, and an Oceans to Forests exhibit with both aquarium and rain forest habitats over the next three years.
Council members were supportive of the zoo's efforts and offerings, though they asked for more details on the zoo's finances.
'Our zoo is one of the best zoos in the world, and it's one of the treasures of our city, so it's budget season, we'll get through this, and you have my support,' Councilman Philip Spinosa said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
J.B. Poindexter & Co., Inc. Acquires Ambulance Manufacturing Leader Demers Braun Crestline Medix
HOUSTON--(BUSINESS WIRE)--J.B. Poindexter & Co., Inc. (JBPCO), a privately held North American manufacturing leader serving the commercial vehicle and specialty manufacturing industries, today announced the acquisition of Demers Braun Crestline Medix (DBCM). 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. Share Headquartered in Beloeil, Quebec (Canada), DBCM is one of North America's largest ambulance manufacturers with a strong presence across the U.S. and Canadian markets. Known for advanced innovation and paramedic-driven design, DBCM has delivered more than 70,000 units to over 40 countries and employs more than 1,500 team members across its operations. 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. 'As JBPCO celebrates its 40th anniversary, and each of the DBCM brands celebrates decades of dedication in the emergency vehicle industry, we are proud to bring together more than 500 years of combined manufacturing excellence across our portfolio of companies. DBCM has built a solid foundation, and we look forward to investing in its future, supporting the team, enhancing the products, and unlocking new opportunities for growth.' Demers recently launched its 11 th -generation ambulance platform and continues to set the bar in safety, design, and performance with paramedic-centric features like the FX Care Module. As part of JBPCO, the Company will continue to operate with brand autonomy while benefiting from expanded resources, shared capabilities, and a culture that values team member contributions. 'Joining JBPCO is a major milestone for our organization and our team,' said Alain Brunelle, CEO of Demers Braun Crestline Medix. 'We are united by a mission to improve lives, one relationship and one vehicle at a time—and this partnership ensures we can continue doing just that, with even greater scale and support.' JBPCO's total revenue will reach $3 billion with this acquisition, reinforcing its role as a cornerstone in the commercial and specialty vehicle manufacturing space—from last-mile delivery and work trucks to emergency response vehicles. About J.B. Poindexter & Co., Inc. J.B. Poindexter & Co., Inc. (JBPCO) is a privately held, diversified manufacturing company providing best-in-class commercial automotive and industrial solutions. JBPCO owns and operates a portfolio of leading business units including Morgan Truck Body, LLC; Morgan Olson, LLC; The Reading Truck Group, LLC; Truck Accessories Group, LLC d/b/a LEER Group; Masterack, LLC; EFP, LLC; Federal Eagle, LLC; and EAVX. JBPCO is headquartered in Houston, Texas and with the acquisition of DBCM, now employs more than 10,000 team members across North America. For more information, visit or connect on LinkedIn. Demers Braun Crestline Medix is one of North America's largest ambulance manufacturers, with a legacy of over 175 years across its four leading brands. Headquartered in Beloeil, Quebec, and operating in both Canada and the United States, the company designs and manufactures ambulances that meet the evolving needs of emergency service providers. Its brands—Demers, Braun, Crestline, and Medix—have delivered over 70,000 units in more than 40 countries. To learn more, visit and
Business Upturn
3 hours ago
- Business Upturn
INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the 'Class Period'), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc. , No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint. The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Yahoo
3 hours ago
- Yahoo
Darden (NYSE:DRI) Reports Q2 In Line With Expectations
Restaurant company Darden (NYSE:DRI) met Wall Street's revenue expectations in Q2 CY2025, with sales up 10.6% year on year to $3.27 billion. Its GAAP profit of $2.58 per share was 12.1% below analysts' consensus estimates. Is now the time to buy Darden? Find out in our full research report. Revenue: $3.27 billion vs analyst estimates of $3.26 billion (10.6% year-on-year growth, in line) EPS (GAAP): $2.58 vs analyst expectations of $2.94 (12.1% miss) EPS (GAAP) guidance for the upcoming financial year 2026 is $10.60 at the midpoint, missing analyst estimates by 1.2% Operating Margin: 11.7%, down from 13.4% in the same quarter last year Free Cash Flow Margin: 8.4%, down from 9.7% in the same quarter last year Locations: 2,159 at quarter end, up from 2,031 in the same quarter last year Same-Store Sales rose 4.6% year on year (0% in the same quarter last year) Market Capitalization: $26.07 billion "We had a strong quarter with same-restaurant sales and earnings growth that exceeded our expectations," said Darden President & CEO Rick Cardenas. Founded in 1968 as Red Lobster, Darden (NYSE:DRI) is a leading American restaurant company that owns and operates a portfolio of popular restaurant brands. Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. With $12.08 billion in revenue over the past 12 months, Darden is one of the most widely recognized restaurant chains and benefits from customer loyalty, a luxury many don't have. Its scale also gives it negotiating leverage with suppliers, enabling it to source its ingredients at a lower cost. However, its scale is a double-edged sword because there is only so much real estate to build restaurants, placing a ceiling on its growth. For Darden to boost its sales, it likely needs to adjust its prices, launch new chains, or lean into foreign markets. As you can see below, Darden's sales grew at a mediocre 6% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts) as it barely increased sales at existing, established dining locations. This quarter, Darden's year-on-year revenue growth was 10.6%, and its $3.27 billion of revenue was in line with Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 8.7% over the next 12 months, an acceleration versus the last six years. This projection is above average for the sector and indicates its newer menu offerings will catalyze better top-line performance. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Darden sported 2,159 locations in the latest quarter. Over the last two years, it has opened new restaurants at a rapid clip by averaging 6.1% annual growth, among the fastest in the restaurant sector. When a chain opens new restaurants, it usually means it's investing for growth because there's healthy demand for its meals and there are markets where its concepts have few or no locations. The change in a company's restaurant base only tells one side of the story. The other is the performance of its existing locations, which informs management teams whether they should expand or downsize their physical footprints. Same-store sales is an industry measure of whether revenue is growing at those existing restaurants and is driven by customer visits (often called traffic) and the average spending per customer (ticket). Darden's demand within its existing dining locations has been relatively stable over the last two years but was below most restaurant chains. On average, the company's same-store sales have grown by 1.7% per year. This performance suggests it should consider improving its foot traffic and efficiency before expanding its restaurant base. In the latest quarter, Darden's same-store sales rose 4.6% year on year. This growth was an acceleration from its historical levels, which is always an encouraging sign. We enjoyed seeing Darden beat analysts' same-store sales expectations this quarter. We were also happy its revenue was in line with Wall Street's estimates. On the other hand, its EPS fell short of Wall Street's estimates. Looking ahead, EPS guidance also came in below expectations. Overall, this was a weaker quarter. The stock remained flat at $221 immediately following the results. Darden didn't show it's best hand this quarter, but does that create an opportunity to buy the stock right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
